114 related articles for article (PubMed ID: 38528728)
1. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
3. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S; López B; Ferreira JP; Girerd N; Bozec E; Pellicori P; Mariottoni B; Cosmi F; Hazebroek M; Verdonschot JAJ; Cuthbert J; Petutschnigg J; Moreno MU; Heymans S; Staessen JA; Pieske B; Edelmann F; Clark AL; Cleland JGF; Zannad F; Díez J; González A;
Eur J Heart Fail; 2022 Feb; 24(2):321-331. PubMed ID: 34841615
[TBL] [Abstract][Full Text] [Related]
4. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
5. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
[TBL] [Abstract][Full Text] [Related]
6. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
[TBL] [Abstract][Full Text] [Related]
7. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
[TBL] [Abstract][Full Text] [Related]
8. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
9. Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: Implication for diagnosis of diastolic heart failure.
Lim TK; Ashrafian H; Dwivedi G; Collinson PO; Senior R
Eur J Heart Fail; 2006 Jan; 8(1):38-45. PubMed ID: 16115798
[TBL] [Abstract][Full Text] [Related]
10. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Kobayashi M; Girerd N; Ferreira JP; Kevin D; Huttin O; González A; Bozec E; Clark AL; Cosmi F; Cuthbert J; Diez J; Edelmann F; Hazebroek M; Heymans S; Mariottoni B; Pellicori P; Petutschnigg J; Pieske B; Staessen JA; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F
Eur J Heart Fail; 2022 Sep; 24(9):1559-1568. PubMed ID: 35703355
[TBL] [Abstract][Full Text] [Related]
11. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction.
Kim H; Jun DW; Cho YK; Nam CW; Han SW; Hur SH; Kim YN; Kim KB
Echocardiography; 2008 Oct; 25(9):961-7. PubMed ID: 18771554
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
[TBL] [Abstract][Full Text] [Related]
13. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Ferreira JP; Verdonschot JAJ; Girerd N; Bozec E; Pellicori P; Collier T; Mariottoni B; Cosmi F; Hazebroek M; Cuthbert J; Petutschnigg J; Heymans S; Staessen JA; Pieske B; Edelman F; Clark AL; Díez J; González A; Rossignol P; Cleland JG; Zannad F
Eur J Heart Fail; 2022 May; 24(5):771-778. PubMed ID: 35199421
[TBL] [Abstract][Full Text] [Related]
14. Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy.
Abbasi SA; Shah RV; McNulty SE; Hernandez AF; Semigran MJ; Lewis GD; Jerosch-Herold M; Kim RJ; Redfield MM; Kwong RY
PLoS One; 2016; 11(11):e0164914. PubMed ID: 27812147
[TBL] [Abstract][Full Text] [Related]
15. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
16. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
[TBL] [Abstract][Full Text] [Related]
18. Relation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and left atrial volume index to left ventricular function in chronic hemodialysis patients.
Yamazaki M; Ogawa T; Tamei N; Ando Y; Nitta K
Heart Vessels; 2011 Jul; 26(4):421-7. PubMed ID: 21127887
[TBL] [Abstract][Full Text] [Related]
19. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
[TBL] [Abstract][Full Text] [Related]
20. Correlation between circulating fibrosis biomarkers with left atrial function and left atrial volume index in rheumatic mitral stenosis.
Asrial AA; Reviono R; Soetrisno S; Setianto BY; Widyaningsih V; Nurwati I; Wasita B; Pudjiastuti A
Narra J; 2024 Apr; 4(1):e293. PubMed ID: 38798862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]